**Rhythm Pharmaceuticals Reports Fiscal Year 2025 Financial Results and Provides Business Update**

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, announced its financial results for the year ended December 31, 2025. The company reported total revenues of $189.8 million, a 46% increase compared to $130.1 million in 2024. This growth was primarily driven by a 50% increase in net product revenue, which reached $194.8 million in 2025, up from $130.1 million in the previous year, reflecting higher sales volumes both domestically and internationally for IMCIVREE. License revenue decreased by $5.0 million due to the termination of the RareStone license agreement.

The company's financial performance also included a decrease in research and development expenses, which totaled $167.3 million in 2025, compared to $238.0 million in 2024. This decrease was primarily due to the absence of acquired In-Process Research and Development (IPR&D) costs related to the acquisition of LG Chem's bivamelagon, which occurred in 2024, as well as the completion or wind-down of several clinical trials. Selling, general, and administrative expenses increased to $194.9 million in 2025, up from $144.3 million in 2024, driven by increased compensation-related costs and higher marketing and promotion expenses. Rhythm Pharmaceuticals reported a net loss of $196.5 million for 2025, compared to a net loss of $260.6 million in 2024.

Operationally, Rhythm Pharmaceuticals highlighted several key developments. The company is preparing for the potential U.S. launch of IMCIVREE for acquired hypothalamic obesity in 2026, pending regulatory approval, with an FDA PDUFA goal date of March 20, 2026. Topline data from a Japanese cohort in a Phase 3 trial for this indication is expected in March 2026, with a new drug application submission planned in Japan. The company also plans to initiate a Phase 3 registrational trial for bivamelagon in patients with hypothalamic obesity by year-end 2026. Furthermore, based on positive preliminary results from a Phase 2 trial, Rhythm is advancing the development of setmelanotide and RM-718 for Prader-Willi syndrome (PWS). As of February 1, 2026, Rhythm Pharmaceuticals had 414 employees, including 126 employees in 11 countries outside of North America.

Looking ahead, Rhythm Pharmaceuticals anticipates continued revenue growth from IMCIVREE and is focused on expanding its clinical development programs. The company expects to report topline data from the Phase 3 EMANATE trial, evaluating setmelanotide in genetically caused MC4R pathway diseases, in March 2026. Rhythm Pharmaceuticals also anticipates nominating a development candidate in 2026 for its congenital hyperinsulinism (CHI) program. The company's cash and cash equivalents and short-term investments totaled $388.9 million as of December 31, 2025, which are expected to fund operations for at least 24 months.

About RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines targeting the MC4R pathway to treat rare genetic and acquired obesity disorders characterized by hyperphagia and severe obesity. Its lead product, IMCIVREE (setmelanotide), is approved for certain syndromic and monogenic obesity conditions. The company advances clinical programs for hypothalamic obesity and other rare diseases, leveraging genetic insights to expand treatment options for underserved patient populations.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.